sunitinib pharmascience 25 mg/1 kapsula kapsula, tvrda
evropa lijek pharma d.o.o. - sunitinib - kapsula, tvrda - 25 mg/1 kapsula - 1 kapsula, tvrda sadrži: 25 mg sunitiniba (u obliku 27,293 mg sunitinib hidrohlorida)
sunitinib pharmascience 50 mg/1 kapsula kapsula, tvrda
evropa lijek pharma d.o.o. - sunitinib - kapsula, tvrda - 50 mg/1 kapsula - 1 kapsula, tvrda sadrži: 50 mg sunitiniba (u obliku 54,585 mg sunitinib hidrohlorida)
sunitinib pharmascience 50 mg/1 kapsula kapsula, tvrda
evropa lijek pharma d.o.o. - sunitinib - kapsula, tvrda - 50 mg/1 kapsula - 1 kapsula, tvrda sadrži: 50 mg sunitiniba (u obliku 54,585 mg sunitinib hidrohlorida)
vidaza
bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
sunitinib pharmascience 12,5 mg tvrde kapsule
pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 12,5 mg sunitiniba u obliku sunitinibklorida
sunitinib pharmascience 25 mg tvrde kapsule
pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 25 mg sunitiniba u obliku sunitinibklorida
sunitinib pharmascience 37,5 mg tvrde kapsule
pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 37,5 mg sunitiniba u obliku sunitinibklorida
sunitinib pharmascience 50 mg tvrde kapsule
pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 50 mg sunitiniba u obliku sunitinibklorida